Ketogenic therapy for Parkinson's disease: A systematic review and synthesis without meta-analysis of animal and human trials
Ημερομηνία
2022Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Objective: The aim of the present systematic review was to assess the efficacy of ketogenic therapy in Parkinson's disease (PD), using all available data from randomized controlled trials (RCTs) on humans and animal studies with PD models. Design: Systematic review of in vivo studies. Methods: Studies related to the research question were identified through searches in PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, clinicaltrials.gov and the gray literature, from inception until November 2021. Rayyan was employed to screen and identify all studies fulfilling the inclusion criteria. Cochrane's revised Risk of Bias 2.0 and SYRCLE tools evaluated bias in RCTs and animal studies, respectively. An effect direction plot was developed to synthesize the evidence of the RCTs. Results: Twelve studies were identified and included in the qualitative synthesis (4 RCTs and 8 animal trials). Interventions included ketogenic diets (KDs), supplementation with medium-chain triglyceride (MCT) oil, caprylic acid administration and ketone ester drinks. The animal research used zebrafish and rodents, and PD was toxin-induced. Based on the available RCTs, ketogenic therapy does not improve motor coordination and functioning, cognitive impairment, anthropometrics, blood lipids and glycemic control, exercise performance or voice disorders in patients with PD. The evidence is scattered and heterogenous, with single trials assessing different outcomes; thus, a synthesis of the evidence cannot be conclusive regarding the efficacy of ketogenic therapy. On the other hand, animal studies tend to demonstrate more promising results, with marked improvements in locomotor activity, dopaminergic activity, redox status, and inflammatory markers. Conclusions: Although animal studies indicate promising results, research on the effect of ketogenic therapy in PD is still in its infancy, with RCTs conducted on humans being heterogeneous and lacking PD-specific outcomes. More studies are required to recommend or refute the use of ketogenic therapy in PD. © 2022 Elsevier B.V.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Higher probability of prodromal Parkinson disease is related to lower cognitive performance
Bougea A., Maraki M.I., Yannakoulia M., Stamelou M., Xiromerisiou G., Kosmidis M.H., Ntanasi E., Dardiotis E., Hadjigeorgiou G.M., Sakka P., Anastasiou C.A., Stefanis L., Scarmeas N. (2019)ObjectiveGiven the limited information on cognitive function before Parkinson disease (PD) clinical onset in the general population, we sought to assess prodromal PD (pPD) probability and relate it to detailed cognitive ... -
Association between Motor Signs and Cognitive Performance in Cognitively Unimpaired Older Adults: A Cross-Sectional Study Using the NACC Database
Siokas V., Liampas I., Lyketsos C.G., Dardiotis E. (2022)Aiming to examine whether specific motor signs are associated with worse performance in specific cognitive domains among cognitively unimpaired (CU) individuals, we performed a cross-sectional analysis of data from the ... -
Plasma Glutathione and Prodromal Parkinson's Disease Probability
Charisis S., Ntanasi E., Stamelou M., Xiromerisiou G., Maraki M., Veskoukis A.S., Yannakoulia M., Kosmidis M.H., Anastasiou C.A., Giagkou N., Dardiotis E., Hadjigeorgiou G., Sakka P., Kouretas D., Stefanis L., Scarmeas N. (2022)Background: A decrease in glutathione (GSH) levels is considered one of the earliest biochemical changes in Parkinson's disease (PD). Objective: The authors explored the potential role of plasma GSH as a risk/susceptibility ...